Royal Bank Of Canada Boosts Pharvaris (NASDAQ:PHVS) Price Target to $62.00

Pharvaris (NASDAQ:PHVS) had its price objective increased by research analysts at Royal Bank Of Canada from $52.00 to $62.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target indicates a potential upside of 64.85% from the company’s current price.

A number of other brokerages have also issued reports on PHVS. Citizens Jmp upped their target price on shares of Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Oppenheimer restated an “outperform” rating and issued a $75.00 price objective on shares of Pharvaris in a research report on Tuesday. HSBC raised Pharvaris to an “overweight” rating in a report on Thursday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $55.23.

Pharvaris Stock Down 0.6%

Pharvaris stock opened at $37.61 on Wednesday. The stock has a 50-day simple moving average of $34.86 and a 200 day simple moving average of $31.20. The stock has a market capitalization of $2.46 billion, a price-to-earnings ratio of -12.37 and a beta of -2.33. Pharvaris has a 12-month low of $20.65 and a 12-month high of $43.25.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, sell-side analysts anticipate that Pharvaris will post -3.15 EPS for the current year.

Insider Transactions at Pharvaris

In other news, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the sale, the director directly owned 315,167 shares of the company’s stock, valued at $11,185,276.83. This represents a 8.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Berndt Modig sold 2,292 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the sale, the chief executive officer owned 130,625 shares in the company, valued at $4,541,831.25. This represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 118,655 shares of company stock worth $4,188,002. 11.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pharvaris

Several large investors have recently bought and sold shares of PHVS. Alyeska Investment Group L.P. raised its position in Pharvaris by 225.5% during the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock valued at $14,068,000 after purchasing an additional 281,829 shares in the last quarter. Seven Fleet Capital Management LP boosted its holdings in shares of Pharvaris by 472.3% in the 1st quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after purchasing an additional 261,355 shares in the last quarter. PSP Research LLC bought a new position in shares of Pharvaris in the 4th quarter valued at $569,000. BlackRock Inc. bought a new position in shares of Pharvaris in the 2nd quarter valued at $26,677,000. Finally, DV Trading LLC bought a new position in shares of Pharvaris in the 1st quarter valued at $4,067,000.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Phase 3 CHAPTER-3 trial met all key objectives: Pharvaris reported statistically significant and clinically meaningful results for the primary endpoint and every secondary efficacy endpoint. Deucrictibant XR reduced HAE attacks, supporting its potential as an oral prophylactic option. Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study
• Positive Sentiment: Regulatory submissions are planned: The company expects to use CHAPTER-3 data in marketing applications beginning in the first half of 2027, marking a significant step toward potential commercialization. Pharvaris’ genetic disorder drug meets main goal in late-stage trial
• Positive Sentiment: Analyst support strengthened: Wedbush maintained an Outperform rating with a $42 target, while RBC raised its target to $62 from $52 and kept an Outperform rating. HC Wainwright also reaffirmed Buy with a $60 target. A separate analyst compilation reported a consensus target of $51.08. RBC Raises Price Target on Pharvaris
• Neutral Sentiment: Key risks remain: Pharvaris is still a clinical-stage, loss-making biotechnology company, and RBC continues to classify the shares as carrying speculative risk. Future performance will depend on regulatory review, additional data and successful commercialization.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.